
According to a new U.S. Congressional Budget Office analysis, President Donald Trump’s 2026 budget plan proposes cuts to the National Institutes of Health that could significantly reduce the number of new drugs entering the market.
The agency projected that slashing NIH funding by billions would gradually erode the pipeline of drug innovation over the coming decades.